C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests